- Open Access
Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI
© Chinnasamy et al; licensee BioMed Central Ltd. 2006
- Received: 13 December 2005
- Accepted: 15 March 2006
- Published: 15 March 2006
A number of gene therapy applications would benefit from vectors capable of expressing multiple genes. In this study we explored the feasibility and efficiency of expressing two or three transgenes in HIV-1 based lentiviral vector. Bicistronic and tricistronic self-inactivating lentiviral vectors were constructed employing the internal ribosomal entry site (IRES) sequence of encephalomyocarditis virus (EMCV) and/or foot-and-mouth disease virus (FMDV) cleavage factor 2A. We employed enhanced green fluorescent protein (eGFP), O6-methylguanine-DNA-methyltransferase (MGMT), and homeobox transcription factor HOXB4 as model genes and their expression was detected by appropriate methods including fluorescence microscopy, flow cytometry, immunocytochemistry, biochemical assay, and western blotting.
All the multigene vectors produced high titer virus and were able to simultaneously express two or three transgenes in transduced cells. However, the level of expression of individual transgenes varied depending on: the transgene itself; its position within the construct; the total number of transgenes expressed; the strategy used for multigene expression and the average copy number of pro-viral insertions. Notably, at limiting MOI, the expression of eGFP in a bicistronic vector based on 2A was ~4 times greater than that of an IRES based vector.
The small and efficient 2A sequence can be used alone or in combination with an IRES for the construction of multicistronic lentiviral vectors which can express encoded transgenes at functionally relevant levels in cells containing an average of one pro-viral insert.
- K562 Cell
- Mean Fluorescence Intensity
- Internal Ribosome Entry Site
- MGMT Protein
- eGFP Positive Cell
Lentiviral vectors are efficient tools for gene transfer into various dividing and non-dividing target cells. They offer several advantages over other vectors, including stable integration into the host cell genome, lack of transfer of viral genes, and a relatively large capacity for therapeutic genes. A number of studies have demonstrated the ability of lentiviral vectors to achieve efficient and sustained transgene expression [1–6] and they have recently been approved for human clinical studies . The majority of preclinical studies undertaken thus far have been conducted with the aim of transferring one therapeutic gene into target cells. However, many potential gene transfer applications require vectors that express more than one protein. These may include a therapeutic gene plus a selectable marker gene, multiple genes encoding different subunits of a complex protein or multiple independent genes that cooperate functionally. A number of strategies are employed in viral vectors to express multiple genes, including mRNA splicing, internal promoters, internal ribosomal entry sites, fusion proteins, and cleavage factors. The most commonly used strategy in the construction of two gene vectors is the insertion of an internal ribosome entry site (IRES) element between the two transgenes . The IRES of encephalomyocarditis virus (EMCV) has been widely used to link two genes transcribed from a single promoter within recombinant viral vectors. However, there are a number of limitations using IRES elements, including their size and variability in expression of transgenes. In many cases it has been reported that a gene transcribed upstream of an IRES is expressed strongly whereas a gene placed downstream is expressed at lower levels [9, 10].
Positive strand RNA viruses generally encode polyproteins that are cleaved by viral or host proteinases to produce mature proteins. Among other mechanisms many of these viruses are also known to contain 2A or similar peptide coding sequences to mediate protein cleavage. Foot and mouth disease virus (FMDV) is a picornavirus with an RNA genome that encodes a single poly-protein of approximately 225 kDa. This polyprotein is cleaved in the host cell to produce different protein products. A self-processing activity in FMDV leads to 'cleavage' between the terminal glycine of the 2A product and the initial proline of 2B. The exact mechanism of 2A/2B cleavage is not known. However, it has been hypothesized that the 2A sequence somehow impairs normal peptide bond formation between 2A glycine and 2B proline through a ribosomal skip mechanism without affecting the translation of 2B. The self-processing activity is conferred on heterologous fusion proteins by ~20 amino acids from the 2A region. The cleavage of the polyprotein product occurs at the C-terminal end of the 2A coding region, leaving this peptide fused to the upstream protein and releasing the downstream protein intact (with the addition of an N-terminal Proline).
Previously the FMDV 2A sequence has been successfully incorporated in to adeno-associated  and retroviral [12, 13] vectors to construct multigene vectors. Multigene lentiviral vectors have been developed by other groups using strategies involving inclusion of IRES , multiple internal promoters [15, 16] and differential splicing moieties . More recently dual-gene lentiviral vectors were developed with synthetic bidirectional promoters .
Since the advent of the serious adverse effects observed in a clinical study of retroviral gene therapy for the treatment of X-linked SCID, it has become apparent that limiting MOI is desirable in order to minimize the risk of insertional mutagenesis [19–21]. Therefore, in order to determine whether the use of multi-cistronic vectors is realistically feasible for gene therapy applications, and to determine the most suitable co-expression strategy, it is essential to compare the performance of different vectors at limiting dilution. Herein we describe the development of HIV-1 based multigene lentiviral vectors using combinations of the FMDV 2A cleavage factor and the EMCV IRES. Bicistronic and tricistronic lentiviral vectors were able to coexpress 2 or 3 different proteins, albeit at levels that depend on the transgene and its location.
Construction of multigene lentiviral vectors
Relative vector titers as measured by HIV-1 p24 gag protein.
383 ± 261
243 ± 92
385 ± 270
368 ± 92
238 ± 126
380 ± 91
Relative expression of MGMT and eGFP
Relative MGMT Expression
Relative eGFP Expression
1.00 ± 0.14
1.00 ± 0.33
0.87 ± 0.14
0.41 ± 0.14
0.80 ± 0.15
0.10 ± 0.02
0.45 ± 0.13
0.06 ± 0.02
0.16 ± 0.04
0.04 ± 0.01
When expression of MGMT activity was determined per proviral copy, it was also clear that the bicistronic vectors showed closely similar levels of expression to each other and to that of the monocistronic MGMT vector (Figure 4B and Table 2). Expression of MGMT-2A-eGFP cassette produces MGMT protein with an extra 23 amino acid peptide fused to C-terminus. The presence of this extra 23 amino acid peptide did not seem to interfere with the activity of MGMT since levels from the IRES vector were comparable (Figure 4B and Table 2).
Next we explored the possibility of directing the expression of three transgenes in a lentiviral vector by using a combination of 2A and IRES sequences. Tricistronic vectors were constructed with the aid of both IRES and 2A sequences connecting the three cDNAs (Figure 1). In these constructs the 2A sequence was used to connect the first two transgene, whilst the third gene was expressed via the IRES sequence. All the remaining components of the vector backbone were the same as those of monocistronic and bicistronic vectors. Two tricistronic lentiviral vectors were constructed as described in methods, HOXB4-2A-MGMT-IRES-eGFP and MGMT-2A-HOXB4-IRES-eGFP.
Currently there are several types of gene delivery vectors available to deliver one or two genes into target cells. An increasing demand for more complex multicistronic vectors has arisen in recent years for various applications both in basic research and clinical gene therapy. Herein we described a new method to coexpress multiple transgenes efficiently in HIV-1 based lentiviral vectors. We constructed bicistronic and tricistronic lentiviral vectors using combinations of a self-processing 2A cleavage factor and IRES and undertook systematic analysis of the expression of selected marker genes. In this report we describe bicistronic and tricistronic lentiviral vectors. These multigene vectors can successfully co-express 2 or 3 transgenes under the direction of a single promoter. All the vectors described in this study produced high titer vector stocks comparable to the monocistronic vectors. They were also able to transduce multiple target cells of human and murine origin efficiently. However, there were differences in the level of transgene expression among the vectors depending on the size, position and total number of transgenes placed within the expression cassette; and type of transgene involved. Bicistronic vectors based on the 2A cleavage factor were more efficient in the co-expression of two transgenes than IRES based vectors. Indeed, co-expression mediated by the 2A motif was superior to internal ribosome entry across a range of different vector MOIs, and it is of import that this differential was maintained at a limiting copy number. Thus, 2A represents an attractive alternative to currently used systems for the co-expression of two proteins in lentiviral vectors.
A major advantage of using the 2A cleavage factor in the construction of multicistronic vectors is its small size compared to internal promoters or IRES sequences. Given the packaging constraints on lentiviral vectors, minimizing the size of sequences required to enable co-expression is important in maximizing the capacity for therapeutic sequences. In addition, efficient co-expression of both genes is ensured as we have shown in the case of MGMT-2A-eGFP. The 2A sequence efficiently promoted the generation of predicted cleavage products from the artificial fusion protein in transduced cells. Previous studies with oncoretroviral [13, 23, 24] and AAV  vectors have shown the feasibility of using the 2A sequence for the expression of multiple transgenes. Incomplete cleavage of 2A mediated fusion products has previously been reported in AAV  and retroviral vectors [12, 25]. In our hands, the efficiency of cleavage was construct dependent, with the MGMT-2A-eGFP cassette leading to some (approximately 6–8%) uncleaved product, whilst those cassettes incorporating HOXB4 showed apparent 100% cleavage. Although the reason for incomplete cleavage remain obscure, it is not unreasonable to speculate that differences in fusion protein secondary structure might influence this.
In addition to efficient generation of cleavage products, it is important that these are transported to the appropriate compartment of the cell where their action is required. As shown by the nuclear localization of HOXB4 and MGMT in our study, the addition of 2A sequences did not adversely affect the trafficking of these two proteins. Recently Szymczak et al  reported the construction of a multicistronic retroviral vector using multiple 2A cleavage factors or similar sequences with efficient coexpression of complete T cell receptor complex proteins. They showed that a 2A like peptide linked retroviral vector could be used to express all of the four CD3 proteins (CD3ε,γ,δ,ζ), appropriately localized to the membrane and that this restored T cell development in CD3 deficient mice. However in another recent report, mistargetting of second gene products was observed dependent on the context in which they were expressed . It will be important; therefore, to empirically test any co-expression cassette to ensure that localization of transgene products is appropriate. Szymczak et al used four separate 2A sequences from different viruses, which share a conserved sequence. To avoid recombination they changed codon usage by introducing silent mutations within 2A sequences. A similar approach in lentiviral vectors might allow efficient delivery of multiple genes linked with multiple 2A cleavage factors without the need to use IRES sequences. However, whether or not recombination would be a problem if identical sequences were used, may be worth establishing.
One particular attraction of this 2A-based strategy is in applications in which it is desirable to coexpress two or more therapeutic genes in comparable amounts as in the case of two subunits of a functional protein (e.g. enzyme, cytokines). Previously described lentiviral vectors based on IRES or multiple internal promoters  have revealed inconsistent levels of expression of individual transgenes within the expression cassette. From our data summarized in Table 2, it is clear that the relative levels of MGMT and eGFP expression from the bicistronic 2A-based vector were higher than IRES based vector. In contrast, expression of eGFP from the IRES-containing vector was around one fifth that of MGMT. Although this is an improvement on other reports of IRES-containing lentiviral vectors , such a discrepancy in expression levels of the upstream and downstream genes would probably be detrimental to certain therapeutic applications. 2A based multigene vectors, thus offer the unique advantage of better coexpression of two or more desired transgenes. It is of particular interest that this comparison was made at limiting MOI using expression cassettes whose transcription was driven by a clinically relevant human cellular promoter. Hence we can conclude that a 2A mediated co-expression strategy is significantly improved over an approach using the EMCV IRES when lentiviral vectors are used to infect cells at a level which is appropriate to gene therapy applications, where a major concern may be minimizing the risk of insertional mutagenesis.
In addition to the potential for intracellular mislocalisation of protein, the addition of 2A peptide [ additional amino acids in this case) to the first gene product might also interfere with the function of a given protein, and again this will have to be determined empirically for each application. In our experience addition of the 2A peptide did not affect the function of MGMT protein as neither its DNA repair activity nor nuclear localization were altered. Moreover, recent studies indicated that HOXB4 expressed using the 2A strategy retains its ability to support hematopoietic reconstitution by murine hematopoietic stem cells [25, 27]. A further issue might be immunogenicity due to the attachment of the 2A peptide-adduct to a therapeutic protein. Although these problems are not encountered in two recent murine in vivo studies [24, 25], further studies in multiple species are needed to understand this issue. More recently Fang et al  successfully engineered a furin cleavage site next to the 2A sequence to eliminate any possible adverse effects that might be caused by having a 2A peptide residue on a therapeutic protein.
In conclusion, we have developed multigene lentiviral vectors, incorporating 2A and IRES sequences that efficiently mediated the co-expression of two or three transgenes in multiple cell types. Multicistronic vectors are useful for various basic laboratory studies and gene therapy applications. They could be used in genetic immunotherapy strategies where more than one gene products are necessary to mount an effective immune response . In chemoprotective strategies, expression of multiple drug resistance genes in hematopoietic stem cells would help to protect the hematopoietic compartment from a variety of cancer chemotherapeutic drugs . These vectors may also be useful for the treatment of neurodegenerative diseases such as Parkinson's disease where up to 3 or 4 genes may be required for the effective production and transportation of dopamine .
The lentiviral vectors used in this study are in pRRL.PPT.PGK.X.W.SIN backbone and pRRL.PPT.PGK.eGFP.W.SIN and pRRL.PPT.PGK.MGMTP140K.W.SIN are described previously . Multigene cassettes were constructed in pSF91m3 vectors and flanked by a 5' Not I site and 3' BamH I site, complete details of construction steps are given in the following paragraph. A sub cloning step was required, in which each pSF91m3 plasmid was digested with the aforementioned restriction enzymes having one or both ends of the expression cassettes filled-in and transferred into pBluescript KS+ or pGEM7zf(-) (Promega, Madison, WI) before final transfer into lentiviral vector pRRL.PPT.PGK.eGFP.W.SIN replacing eGFP at the BamH I and Sal I sites.
The expression cassettes: MGMTP140K-2A-eGFP and HOXB4-2A-MGMTP140K-IRES-eGFP and have been previously described . In brief: (i) HOXB4-2A-MGMT P140K -IRES-eGFP. HOXB4 was amplified from its cDNA using the oligonucleotides TTGCGGCCGCCATGGCTATGAGTTCTTTTTTGATC and TTCTCGAGAGAGCGCGCGGGGGCCTC, following which it was digested with Not I and Xho I. FMDV 2A was amplified using the oligonucleotides TTCTCGAGTGAAACAGACTTTGAATTTTGACC and CCGGTGGATCCCATAGAATTCC, following which it was digested with Xho I and Bam H I. MGMTP140K was amplified from its cDNA using the oligonucleotides GGTACCCGGAGATCTATGGACAAGG and TTGGATCCTCAGTTTCGGCCAGCAGG, following which it was digested with Bgl II and Bam H I. The EMCV IRES was amplified from pIRES2-eGFP (Clontech) using the oligonucleotides TACCGCGGGCCCGAGATCTGCCCCTCTC and CCGGATCCCATGGTTGTGGCCATATTATCA, followed by digest with Bgl II and Bam H I. eGFP was also amplified from pIRES2-eGFP using the primers GACTCTAGAAGATCTATGGTGAGC and TTGGATCCTTACTTGTACAGCTC, following which it was digested with Bgl II and Bam H I. The HOXB4-2A-MGMTP140K-IRES-eGFP cassette was then sequentially assembled as a Not I/Bam H I restriction fragment. (ii) MGMT P140K -2A-HOXB4-IRES-eGFP. MGMT was amplified from its cDNA using the oligonucleotides TTGCGGCCGCCATGGACAAGGATTGTGAAATG and TTCTCGAGAGTTTCGGCCAGCAGGC, following which it was digested with Not I and Xho I. FMDV 2A was amplified as described in (i), followed by digestion with Xho I and Eco R I. HOXB4 was amplified from its cDNA using the oligonucleotides TTGAATTCTATGGCTATGAGTTCTTTTTTGATC and TTGGATCCCTAGAGCGCGCGGGGGCCTC, followed by digest with Eco R I and Bam H I. Both the EMCV IRES and eGFP were isolated and digested as described in (i). The MGMTP140K-2A-HOXB4-IRES-eGFP cassette was then sequentially assembled as a Not I/Bam H I fragment. (iii) MGMT P140K -2A-eGFP. MGMTP140K was amplified and digested as described in (ii). Both FMDV 2A and eGFP were isolated and digested as described in (i). The MGMTP140K-2A-eGFP cassette was then sequentially assembled as a Not I/Bam H I fragment. (iv) MGMT P140K -IRES-eGFP. MGMTP140K, EMCV IRES and eGFP were amplified and digested as described in (i). The MGMTP140K-IRES-eGFP cassette was then sequentially assembled as a Bgl II/Bam H I fragment.
K562 and Hela cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The human embryonic kidney cell line 293T and Hela cells were cultured at 37°C with 5% CO2 in Dulbecco Modified Eagle's Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (HyClone, CA). K562 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 2 mM glutamine.
Virus production and titering
Replication-defective lentiviral vector particles were produced by 3-plasmid transient transfection of 293T cells as previously reported . Briefly, 293T cells plated to ~70% confluency are cotransfected with pMD.G, pCMVΔR8.91, and the appropriate gene transfer vector plasmid by calcium phosphate transfection method. Viral particles were concentrated by centrifugation at 50,000×g for 90 minutes. The resulting pellets were resuspended in X-VIVO 10 medium (Cambrex Bio Science, Walkersville, MD) and stored at -80°C. Concentrated viral preparations were tested by ELISA for HIV-1 p24 (gag) antigen. The possibility of the generation of replication-competent lentivirus (RCL) was tested by checking for the presence of the viral protein p24 in the culture media of stably transduced 293T cells. All the samples tested were negative for RCL particles.
Lentiviral transduction of K562 and Hela cells
K562 and Hela cells were transduced with lentiviral vectors at various multiplicity of infection (MOI) in the presence of 10 μg/ml protamine sulphate. Transduced cells were washed 48 hours after transduction and analyzed 7 days later. An aliquot of the transduced cells was cultured over a period of 6 months to study the long-term gene expression. Whole-cell population was used rather than selected clones in all of our experiments.
Flow cytometric analysis
Fluorescence-activated cell sorter (FACS) analysis was carried out for the detection of cellular expression of eGFP using a FACScan flow cytometer (Beckton-Dickinson) with the FL1 detector channel. The data were acquired and analyzed with CellQuest software (BD). Untransduced cells were used as controls. Mean fluorescence intensity (MFI) was used as an indicator of relative expression of eGFP on given cells. Results were presented as a percent of positive cells and MFI.
Lentivirally transduced and untransduced control K562 cells were harvested 4 weeks following the transduction and the biochemical activity of MGMT in the cell extracts were determined by quantitation of the transfer of [3H]-methyl groups from [3H]-MNU-methylated calf thymus DNA substrate to MGMT protein as described previously [22, 33]. MGMT activity was presented as femto moles of methyl group transferred per milligram of total protein. Protein concentrations in the cell extracts were determined by Bradford assay using bovine serum albumin (BSA) as standard.
Western blot analysis was carried out to assess expression of B-actin, eGFP and MGMT proteins in transduced cells. Cell extracts containing 5 μg of protein were loaded onto polyacrylamide gel and separated. Proteins were transferred to PVDF membranes and blocked in 5% nonfat milk in TBS. The membrane was briefly washed with TBS/Tween and incubated with mouse monoclonal anti human β-actin (Sigma, St. Louis, MO), mouse monoclonal anti GFP (Clontech) or rabbit antihuman MGMT antisera over night at 4°C. The membrane was then washed and incubated with appropriate horseradish peroxidase conjugated secondary antibody for one hour at room temperature. The membrane was put through a final wash step and incubated with chemiluminescent substrate (Pierce, Rockford, IL) for five minutes at room temperature before being exposed to autoradiography film.
Total RNA was isolated from transduced K562 cells using RNeasy kit (Qiagen, Chatsworth, CA). RNA (10 μg per lane) samples were subjected to electrophoresis through a 1% denaturing formaldehyde agarose gel and transferred to a nylon membrane by capillary blotting. The blot was then hybridized with a WPRE specific probe, labeled with the Roche PCR DIG probe synthesis kit and Roche High Prime DNA labeling and detection kit (Roche Diagnostics GmbH, Mannheim, Germany) and the signal detected using Biomax Light Film.
Immunocytochemistry was performed to detect the expression and intracellular localization of MGMT and HOXB4 proteins in transduced cells. Cytospin preparations of transduced K562 cells and Hela cells grown on the chamber slides were stained with rabbit anti human MGMT antiserum  or rat anti human HOXB4 antibody (University of Iowa, Clone I12). Biotin conjugated goat anti rabbit or goat anti rat IgG was used as a secondary antibody and then a horseradish peroxidase conjugated avidin-biotin system (Dako, Carpinteria, CA) was used to detect MGMT or HOXB4 with Diaminobenzidine (DAB) as chromogen. The slides were examined using a Nikon microscope, and the images were captured and analyzed using Image Pro plus® image analysis software.
DNA isolation and analysis of transgene copy number by real-time PCR
DNA was isolated from transduced K562 cells using QIAmp kit (Qiagen) and concentrations measured with a spectrophotometer. The real time PCR analysis was carried out as previously described using primers specific for sequences located within WPRE region of the vector to determine copy numbers . The average copy number of the transgene in genomic DNA isolated from transduced K562 cells was determined using the ABI 7900 sequence detection system and TaqMan chemistries (Applied Biosystems, Foster City, CA). In all the real time PCR analysis a single-copy eGFP lentiviral transgene containing DNA sample from a clone of 293T cells were included as reference control.
Analysis of variance and Tukey's studentized range test were used to determine the significance of the differences in HIV-1 Gag (p24) levels in the vector supernatants.
Lentiviral vector plasmids pRRL.PPT.PGK.eGFP.W.SIN, pCMVΔR8.91 and pMD.G were kindly provided by Dr. Didier Trono, Department of Genetics and Microbiology, CMU, Geneva, Switzerland. The authors thank Mr. Jerry Anderson for statistical analysis and Dr. Christopher Baum for critical review of the manuscript. This work was supported by Aurora Health Care, Inc. The remaining authors wish to dedicate this manuscript to the memory of Dr. Leslie J. Fairbairn.
- Chinnasamy N, Chinnasamy D, Toso JF, Lapointe R, Candotti F, Morgan RA, Hwu P: Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum Gene Ther 2000, 11: 1901-1909. 10.1089/10430340050129512View ArticlePubMedGoogle Scholar
- Levasseur DN, Ryan TM, Pawlik KM, Townes TM: Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 2003, 102: 4312-4319. 10.1182/blood-2003-04-1251View ArticlePubMedGoogle Scholar
- Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D: Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295: 868-872. 10.1126/science.1067081View ArticlePubMedGoogle Scholar
- Pfeifer A, Ikawa M, Dayn Y, Verma IM: Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci U S A 2002, 99: 2140-2145. 10.1073/pnas.251682798PubMed CentralView ArticlePubMedGoogle Scholar
- Piacibello W, Bruno S, Sanavio F, Droetto S, Gunetti M, Ailles L, Santoni S, Viale A, Gammaitoni L, Lombardo A, Naldini L, Aglietta M: Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood 2002, 100: 4391-4400. 10.1182/blood.V100.13.4391View ArticlePubMedGoogle Scholar
- Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, Dull T, McArthur JG: Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol 2002, 20: 53-57. 10.1038/nbt0102-53View ArticlePubMedGoogle Scholar
- Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B: Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004, 9: 902-913. 10.1016/j.ymthe.2004.03.005View ArticlePubMedGoogle Scholar
- Ngoi SM, Chien AC, Lee CG: Exploiting internal ribosome entry sites in gene therapy vector design. Curr Gene Ther 2004, 4: 15-31. 10.2174/1566523044578095View ArticlePubMedGoogle Scholar
- Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T: IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000, 1: 376-382. 10.1006/mthe.2000.0050View ArticlePubMedGoogle Scholar
- Zhou Y, Aran J, Gottesman MM, Pastan I: Co-expression of human adenosine deaminase and multidrug resistance using a bicistronic retroviral vector. Hum Gene Ther 1998, 9: 287-293.View ArticlePubMedGoogle Scholar
- Furler S, Paterna JC, Weibel M, Bueler H: Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons. Gene Ther 2001, 8: 864-873. 10.1038/sj.gt.3301469View ArticlePubMedGoogle Scholar
- de Felipe P, Martin V, Cortes ML, Ryan M, Izquierdo M: Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther 1999, 6: 198-208. 10.1038/sj.gt.3300811View ArticlePubMedGoogle Scholar
- Klump H, Schiedlmeier B, Vogt B, Ryan M, Ostertag W, Baum C: Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther 2001, 8: 811-817. 10.1038/sj.gt.3301447View ArticlePubMedGoogle Scholar
- Stripecke R, Cardoso AA, Pepper KA, Skelton DC, Yu XJ, Mascarenhas L, Weinberg KI, Nadler LM, Kohn DB: Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 2000, 96: 1317-1326.PubMedGoogle Scholar
- Reiser J, Lai Z, Zhang XY, Brady RO: Development of multigene and regulated lentivirus vectors. J Virol 2000, 74: 10589-10599. 10.1128/JVI.74.22.10589-10599.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Yu X, Zhan X, D'Costa J, Tanavde VM, Ye Z, Peng T, Malehorn MT, Yang X, Civin CI, Cheng L: Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther 2003, 7: 827-838. 10.1016/S1525-0016(03)00104-7View ArticlePubMedGoogle Scholar
- Zhu Y, Planelles V: A multigene lentiviral vector system based on differential splicing. Methods Mol Med 2003, 76: 433-448.PubMedGoogle Scholar
- Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L: Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005, 23: 108-116. 10.1038/nbt1049View ArticlePubMedGoogle Scholar
- Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint BG, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302: 415-419. 10.1126/science.1088547View ArticlePubMedGoogle Scholar
- Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z, Kamino K, von Neuhoff N, Schlegelberger B, Kuehlcke K, Bunting KD, Schmidt S, Deichmann A, Von Kalle C, Fehse B, Baum C: Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005, 105: 4235-4246. 10.1182/blood-2004-11-4535View ArticlePubMedGoogle Scholar
- Von Kalle C, Fehse B, Layh-Schmitt G, Schmidt M, Kelly P, Baum C: Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. Semin Hematol 2004, 41: 303-318. 10.1053/j.seminhematol.2004.07.007View ArticlePubMedGoogle Scholar
- Chinnasamy D, Fairbairn LJ, Neuenfeldt J, Treisman JS, Hanson JPJ, Margison GP, Chinnasamy N: Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum Gene Ther 2004, 15: 758-769. 10.1089/1043034041648417View ArticlePubMedGoogle Scholar
- de Felipe P, Izquierdo M: Tricistronic and tetracistronic retroviral vectors for gene transfer. Hum Gene Ther 2000, 11: 1921-1931. 10.1089/10430340050129530View ArticlePubMedGoogle Scholar
- Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA: Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004, 22: 589-594. 10.1038/nbt957View ArticlePubMedGoogle Scholar
- Milsom MD, Woolford LB, Margison GP, Humphries RK, Fairbairn LJ: Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O(6)-methylguanine-DNA-methyltransferase and HOXB4. Mol Ther 2004, 10: 862-873. 10.1016/j.ymthe.2004.07.019View ArticlePubMedGoogle Scholar
- de Felipe P, Ryan MD: Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences. Traffic 2004, 5: 616-626. 10.1111/j.1398-9219.2004.00205.xView ArticlePubMedGoogle Scholar
- Schiedlmeier B, Klump H, Will E, Arman-Kalcek G, Li Z, Wang Z, Rimek A, Friel J, Baum C, Ostertag W: High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation. Blood 2003, 101: 1759-1768. 10.1182/blood-2002-03-0767View ArticlePubMedGoogle Scholar
- Fang J, Qian JJ, Yi S, Harding TC, Tu GH, Vanroey M, Jooss K: Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005, 23: 584-590. 10.1038/nbt1087View ArticlePubMedGoogle Scholar
- Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J: Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res 2005, 11: 1597-1607. 10.1158/1078-0432.CCR-04-1609View ArticlePubMedGoogle Scholar
- Sorrentino BP: Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2002, 2: 431-441. 10.1038/nrc823View ArticlePubMedGoogle Scholar
- Sun M, Zhang GR, Kong L, Holmes C, Wang X, Zhang W, Goldstein DS, Geller AI: Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum Gene Ther 2003, 14: 415-424. 10.1089/104303403321467180PubMed CentralView ArticlePubMedGoogle Scholar
- Chinnasamy D, Chinnasamy N, Enriquez MJ, Otsu M, Morgan RA, Candotti F: Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 2000, 96: 1309-1316.PubMedGoogle Scholar
- Watson AJ, Margison GP: O6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 2000, 152: 49-61.PubMedGoogle Scholar
- Lee SM, Rafferty JA, Elder RH, Fan CY, Bromley M, Harris M, Thatcher N, Potter PM, Altermatt HJ, Perinat-Frey T, Margison GP: Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma. Br J Cancer 1992, 66: 355-360.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.